Variable | Categories | n (%) | Percentiles of dense area | |
---|---|---|---|---|
Median (IQR)# | ||||
 |  |  | Cumulus | AutoDensity |
Age group (years) | 40-49 | 581 (9%) | 76 (53, 91) | 69 (46, 86) |
50-54 | 1,201 (19%) | 63 (36, 82) | 60 (36, 81) | |
55-59 | 1,282 (20%) | 52 (27, 77) | 51 (25, 75) | |
60-64 | 1,214 (19%) | 45 (23, 69) | 44 (22, 70) | |
65-69 | 1,192 (19%) | 39 (19, 64) | 41 (20, 69) | |
70-79 | 857 (14%) | 40 (18, 64) | 41 (21, 69) | |
 |  | z = -21.0, P < 0.001* | z = -16.0, P < 0.001* | |
Hormone therapy use at screening | No | 4,909 (78%) | 47 (23, 72) | 47 (23, 73) |
Yes | 1,418 (23%) | 64 (37, 83) | 62 (37, 81) | |
 |  | χ2 = 179.9, p < 0.001†| χ2 = 127.0, p < 0.001†| |
Family history of breast cancer | No | 6,111 (97%) | 51 (25, 76) | 50 (25, 75) |
Yes | 216 (3%) | 50 (27, 74) | 56 (27, 76) | |
 |  | χ2 = 0.2, P = 0.630†| χ2 = 1.4, P = 0.235†| |
Region of birth | Australia | 4,109 (65%) | 50 (25, 76) | 51 (26, 76) |
Europe/North America | 1,782 (28%) | 51 (26, 75) | 49 (23, 75) | |
Asia | 237 (4%) | 58 (30, 78) | 54 (40, 71) | |
Other | 198 (3%) | 53 (27, 80) | 52 (40, 71) | |
 |  | χ2 = 4.7, P = 0.194†| χ2 = 4.8, P = 0.187†| |
Breast symptoms | None | 5,964 (94%) | 50 (25, 75) | 50 (25, 75) |
No significant symptoms | 363 (13%) | 62 (35, 81) | 59 (29, 79) | |
 |  | χ2 = 20.4, P <0.001†| χ2 = 6.0, P = 0.014†| |
Screening round | First | 2,818 (45%) | 50 (25, 76) | 51 (26, 77) |
Subsequent | 3,509 (55%) | 51 (26, 75) | 50 (24, 75) | |
 |  | χ2 = 0.1, P = 0.715†| χ2 = 3.6, P = 0.059†| |
Screening outcome | Small screen-detected cancers | 653 (10%) | 46 (23, 74) | 47 (25, 78) |
Large screen-detected cancers | 332 (5%) | 58 (37, 79) | 53 (36, 80) | |
Interval cancers | 367 (6%) | 67 (44, 86) | 70 (47, 88) | |
No cancer (controls) | 4,975 (79%) | 49 (24, 74) | 49 (23, 74) | |
 |  | χ2 = 109.5, P < 0.001†| χ2 = 123.1, P < 0.001†|